Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

INTRODUCTION: The safety and efficacy of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β “trap”) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1),...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Thorac Oncol
Auteurs principaux: Paz-Ares, Luis, Kim, Tae Min, Vicente, David, Felip, Enriqueta, Lee, Dae Ho, Lee, Ki Hyeong, Lin, Chia-Chi, Flor, Maria Jose, Di Nicola, Massimo, Alvarez, Rosa Maria, Dussault, Isabelle, Helwig, Christoph, Ojalvo, Laureen S., Gulley, James L., Cho, Byoung Chul
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8210474/
https://ncbi.nlm.nih.gov/pubmed/32173464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2020.03.003
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires